- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05374993
Eine frühe Machbarkeitsbewertung eines neuartigen 3rdMolarTooth Bud-Ablationsverfahrens (Zero3)
The goal of this single-arm prospective, non-randomized study is to demonstrate microwave ablation and agenesis of 3rd molar tooth buds using the Zero3 System in participants that have 3rd molar tooth bud(s) without the formation of enamel (calcification). The main question it aims to answer is the safety of the ablation procedure. Also effectiveness of 3rd molar tooth bud ablation and resulting agenesis will be assessed.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
TriAgenics has developed a highly controllable, safe means of suppressing development of third molar tooth buds. Its unique Zero3 micro-ablation handpiece delivers microwave energy that results in spherical zones of ablation. The Zero3 treatment works by gently warming the wisdom tooth bud from the center outwards in a controlled fashion to ablate the tooth bud tissue and prevent it from being able to form a tooth.
The image-guided Zero3 procedure employs a simple puncture of the tooth bud followed by a 25-95 second ablation cycle. Because of the high level of control enabled by the image-guided ablation, the ablation zone matches the size of the tooth bud with no unplanned cell damage outside the bony crypt of the tooth bud. This results in a procedure with a fully enclosed surgical field with virtually no surgical trauma.
Microwave ablation of tooth buds for eligible children will be performed on day 0 and adverse events and progression of tooth bud effects will be monitored over time after the procedure. Participants will return to the dentist at 1, 7, 30, and 90 days post-procedure for assessment of the treatment site. Participants will exit the study at 90 days unless further monitoring is warranted. If further monitoring does occur, it will only be for an additional 90 days.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Dave Watson
- Telefonnummer: +1 541-527-1810
- E-Mail: davewatson@triagenics.com
Studieren Sie die Kontaktsicherung
- Name: Thomas Lawson, PhD
- Telefonnummer: +1 510-206-1794
- E-Mail: drthomlawson@gmail.com
Studienorte
-
-
Panamá Province
-
Panama City, Panamá Province, Panama
- Universidad Interamericana de Panamá
-
Kontakt:
- ARISTIDES JOEL CASTILLO VÁSQUEZ, DDS
- Telefonnummer: +507 6781-8001
- E-Mail: Dr.ajcastillov@gmail.com
-
Kontakt:
- VIRGILIO B. CASTILLERO D, DDS
- Telefonnummer: +50766799195
- E-Mail: vicas21@yahoo.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participant has radiographic evidence of at least one mandibular 3rd molar tooth bud between 4 and 8 mm in largest diameter, which typically presents in children between 8 and 12 years of age, and
- Participant is free from any clinically significant health or behavioral problems that the investigator determines will be inappropriate for inclusion in the Study, and
- Participant has normal facial and oral anatomy and is free from any abnormality or condition which may impact the performance of the procedure, and
- Participant's parent or legal guardian is willing and able to sign the approved Informed Consent Form ("ICF") and the Participant will agree with the Participant Assent Form and the Participant is willing and able to provide age-appropriate assent and comply with required study procedures and follow-up.
Exclusion Criteria:
- Participant where use of local anesthetic is contraindicated, or
- Participant has any behavioral or medical condition which, in the opinion of the Investigator, would prevent adequate performance of the procedure or affect the health and/or safety of the Participant, or
- Participants with orthodontics (traditional braces or clear aligners), or
- Participant is immunocompromised, has a history of or potential for bone tissue defects, or has any known sensitivities to anesthetic agents, or Exclusion Post Radiological Exam (by Sponsor) from review of the LL8/#17 and LR8/#32 tooth buds
- Adjacent 2nd molar has incomplete enamel formation, or
- Tooth bud has enamel formation (calcification) visible on radiographs, or
- Tooth bud has a diameter of less than 4 mm or greater than 8 mm, or
- Tooth bud has less than 3 mm separation from the inferior alveolar nerve canal.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Machbarkeit des Geräts
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Zero3 Procedure
|
Induce third molar tooth bud agenesis |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of puncture site wound healing
Zeitfenster: 1, 7, 30, and 90 days after the procedure
|
The site of the puncture of the electrode will be visually evaluated by the treating dentist. Success is defined as greater than 90% healing of the puncture site by 90 days after the procedure by visual evaluation by the investigator. |
1, 7, 30, and 90 days after the procedure
|
|
Incidence of Adverse Events
Zeitfenster: 1, 7, 30, and 90 days after the procedure.
|
Serious adverse events related to the procedure. Reviewed by the Medical Monitor and classify each as serious or not serious. |
1, 7, 30, and 90 days after the procedure.
|
|
Pain during and after the procedure
Zeitfenster: Before being released on the day of the procedure and then 1, 7, 30, and 90 days after the procedure
|
The participant will be asked to rank the pain using the Faces Pain Scale-Revised after and then at each monitoring visit. Mean pain scale will be determined for all participants. |
Before being released on the day of the procedure and then 1, 7, 30, and 90 days after the procedure
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Radiographic evidence of treated third molar formation after treatment
Zeitfenster: 30 and 90 days after the treatment
|
Periodical x-ray images will be taken at intervals after the treatment to document any third molar mineralization tooth structure formation after the treatment. Presence of tooth structure will be assessed by the Sponsor, the investigator, and the Medical Monitor. |
30 and 90 days after the treatment
|
|
Diameter of bony crypts after treatment
Zeitfenster: 30 and 90 days after the treatment
|
The maximum diameter of the boney crypt will be compared on per-op and post-op x-rays. Reduction in diameter of boney crypts will be measured and calibrated using the first molar anterior/posterior size as a reference. |
30 and 90 days after the treatment
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Leigh Colby, DDS, TriAgenics Inc
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- TP-025
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .